← Patent-cliff monitor small molecule NEXPLANON ETONOGESTREL
Loss of exclusivity July 2030 latest FDA-listed patent expiry
Company Organon → See this company's full patent-cliff portfolio Drug detail Brand name NEXPLANON Active ingredient ETONOGESTREL Strength 68MG/IMPLANT Dosage form IMPLANT Route IMPLANTATION Modality Small molecule FDA approval May 2011 Marketing status RX
Listed patents Patent Expires Type 9757552 July 2030 product 8722037 September 2027 product 10821277 May 2027 product 8888745 August 2026 product
Regulatory exclusivity Code Expires D-199 January 2029
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.